Novel Biomimetic Reconstituted Built-in Adjuvanted Hepatitis B Vaccine for Transcutaneous Immunization
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved..
Transcutaneous immunization is the administration of a vaccine on the skin to generate efficient systemic and mucosal immune responses against an antigen. In the present study, reconstituted hepatitis B surface antigen vesicles (HBsAg-REVs) integrated with monophosphoryl lipid A were prepared by the delipidation-reconstitution method and tested as built-in adjuvanted vaccine, system for transcutaneous immunization using a combined approach of tape strippings, and enhanced antigen skin contact time. Prepared vesicles were extensively characterized for size, shape, zeta potential, and antigen protein loading efficiency. Following topical application, HBsAg-REVs skin permeation on isolated rat skin and cell uptake by bone marrow-derived dendritic cells were determined by confocal laser scanning microscopy and flow cytometry, respectively. The humoral and cellular immune responses elicited by HBsAg-REVs via transcutaneous immunization were comparable to the marketed intramuscular hepatitis B vaccine formulation with predefined immunization protocols. This study supports that delivery of reconstituted HBsAg vesicles via transcutaneous route may open a new vista for designing topical vaccines with possible immune protection against hepatitis B in future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical sciences - 108(2019), 11 vom: 15. Nov., Seite 3550-3559 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaurav, Monika [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.09.2020 Date Revised 08.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xphs.2019.07.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299606651 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299606651 | ||
| 003 | DE-627 | ||
| 005 | 20231225100711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xphs.2019.07.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299606651 | ||
| 035 | |a (NLM)31348940 | ||
| 035 | |a (PII)S0022-3549(19)30442-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaurav, Monika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Biomimetic Reconstituted Built-in Adjuvanted Hepatitis B Vaccine for Transcutaneous Immunization |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2020 | ||
| 500 | |a Date Revised 08.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Transcutaneous immunization is the administration of a vaccine on the skin to generate efficient systemic and mucosal immune responses against an antigen. In the present study, reconstituted hepatitis B surface antigen vesicles (HBsAg-REVs) integrated with monophosphoryl lipid A were prepared by the delipidation-reconstitution method and tested as built-in adjuvanted vaccine, system for transcutaneous immunization using a combined approach of tape strippings, and enhanced antigen skin contact time. Prepared vesicles were extensively characterized for size, shape, zeta potential, and antigen protein loading efficiency. Following topical application, HBsAg-REVs skin permeation on isolated rat skin and cell uptake by bone marrow-derived dendritic cells were determined by confocal laser scanning microscopy and flow cytometry, respectively. The humoral and cellular immune responses elicited by HBsAg-REVs via transcutaneous immunization were comparable to the marketed intramuscular hepatitis B vaccine formulation with predefined immunization protocols. This study supports that delivery of reconstituted HBsAg vesicles via transcutaneous route may open a new vista for designing topical vaccines with possible immune protection against hepatitis B in future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a TLR-4 agonist | |
| 650 | 4 | |a hepatitis B | |
| 650 | 4 | |a reconstituted vesicles | |
| 650 | 4 | |a transcutaneous immunization | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Adjuvants, Pharmaceutic |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis B Vaccines |2 NLM | |
| 700 | 1 | |a Kumar, Rajendra |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Ravi Shankar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical sciences |d 1961 |g 108(2019), 11 vom: 15. Nov., Seite 3550-3559 |w (DE-627)NLM000006394 |x 1520-6017 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2019 |g number:11 |g day:15 |g month:11 |g pages:3550-3559 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xphs.2019.07.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2019 |e 11 |b 15 |c 11 |h 3550-3559 | ||